Copyright © Daily Dive SA
BusinessTech
Aspen Pharmacare Holdings Ltd. is set to launch its own generic diabetes and obesity drugs next year, aiming to address global supply shortages and affordability concerns. CEO Stephen Saad sees this as a major opportunity, particularly in emerging markets. The company’s shares surged 13% on the news, with existing partnerships with Eli Lilly & Co. and Novo Nordisk A/S in place.
Read More from source
